Clinical Trials
15 trialsNCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00625898 2020-09-10
BETH
NSABP Foundation Inc
Phase 3 Terminated
NCT01690325 2018-08-13
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
West German Study Group
Phase 2 Terminated
NCT00176488 2017-03-23
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00912444 2016-11-22
NATT
Shanghai Jiao Tong University School of Medicine
Phase 3 Terminated
NCT00066807 2016-10-28
PERCHE
ETOP IBCSG Partners Foundation
Phase 3 Terminated
NCT01985841 2015-10-08
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00053911 2014-12-16
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
UNICANCER
Phase 3 Terminated
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01301040 2013-08-30
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
Jules Bordet Institute
Phase 2 Terminated
NCT00431795 2013-02-13
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00193024 2011-05-03
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00162812 2008-07-18
TOP
Jules Bordet Institute
Phase 2 Terminated